KR102221499B1 - 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체 - Google Patents

위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체 Download PDF

Info

Publication number
KR102221499B1
KR102221499B1 KR1020167010897A KR20167010897A KR102221499B1 KR 102221499 B1 KR102221499 B1 KR 102221499B1 KR 1020167010897 A KR1020167010897 A KR 1020167010897A KR 20167010897 A KR20167010897 A KR 20167010897A KR 102221499 B1 KR102221499 B1 KR 102221499B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
pgf2α
skin
atrophic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167010897A
Other languages
English (en)
Korean (ko)
Other versions
KR20160055941A (ko
Inventor
워런 제이. 쉐러
Original Assignee
갈데르마 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈데르마 소시에떼아노님 filed Critical 갈데르마 소시에떼아노님
Publication of KR20160055941A publication Critical patent/KR20160055941A/ko
Application granted granted Critical
Publication of KR102221499B1 publication Critical patent/KR102221499B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • External Artificial Organs (AREA)
KR1020167010897A 2013-09-26 2014-09-26 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체 Expired - Fee Related KR102221499B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361960740P 2013-09-26 2013-09-26
US61/960,740 2013-09-26
PCT/IB2014/002746 WO2015044788A1 (en) 2013-09-26 2014-09-26 Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring

Publications (2)

Publication Number Publication Date
KR20160055941A KR20160055941A (ko) 2016-05-18
KR102221499B1 true KR102221499B1 (ko) 2021-03-02

Family

ID=52282772

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167010897A Expired - Fee Related KR102221499B1 (ko) 2013-09-26 2014-09-26 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체

Country Status (11)

Country Link
US (1) US10039770B2 (enExample)
EP (1) EP3049088B1 (enExample)
JP (1) JP6453318B2 (enExample)
KR (1) KR102221499B1 (enExample)
CN (1) CN105658221B (enExample)
AU (1) AU2014326298B2 (enExample)
BR (1) BR112016006426A2 (enExample)
CA (1) CA2924460A1 (enExample)
MX (1) MX374476B (enExample)
RU (1) RU2690183C2 (enExample)
WO (1) WO2015044788A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6659819B2 (ja) * 2015-07-09 2020-03-04 ガルデルマ・ソシエテ・アノニム 化学療法に関連する脱毛の軽減方法
CN106929477B (zh) * 2017-03-20 2020-01-10 江南大学 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120251613A1 (en) 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
RU2195889C2 (ru) * 1999-05-24 2003-01-10 Парамонов Борис Алексеевич Способ дермабразии
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
EP2278993A4 (en) * 2008-05-16 2012-09-12 Corthera Inc METHOD FOR PROMOTING HEALING
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
CN102031260A (zh) * 2010-08-24 2011-04-27 苏州圣诺生物医药技术有限公司 促进皮肤伤口无疤痕愈合的siRNA及应用
EP3178465A1 (en) * 2010-12-06 2017-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
AU2012212481A1 (en) * 2011-01-31 2013-08-22 Allergan, Inc. Method of enhancing hair growth
WO2014179263A1 (en) * 2013-04-30 2014-11-06 Allergan, Inc. Therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120251613A1 (en) 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue

Also Published As

Publication number Publication date
JP6453318B2 (ja) 2019-01-16
CN105658221A (zh) 2016-06-08
RU2016110925A (ru) 2017-11-01
AU2014326298A1 (en) 2016-04-07
CN105658221B (zh) 2022-05-10
MX2016003650A (es) 2016-06-24
WO2015044788A1 (en) 2015-04-02
US10039770B2 (en) 2018-08-07
EP3049088A1 (en) 2016-08-03
RU2016110925A3 (enExample) 2018-07-13
EP3049088B1 (en) 2021-02-17
RU2690183C2 (ru) 2019-05-31
KR20160055941A (ko) 2016-05-18
US20160228453A1 (en) 2016-08-11
AU2014326298B2 (en) 2019-07-04
MX374476B (es) 2025-03-06
JP2016531872A (ja) 2016-10-13
CA2924460A1 (en) 2015-04-02
BR112016006426A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
KR101457789B1 (ko) 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법
JP6966455B2 (ja) 侵襲的且つ非侵襲的な処置上のスキンケアのための組成物及び方法
RU2530604C2 (ru) Инъецируемая комбинация агонистов адренергических рецепторов с наполнителями для уменьшения кожных реакций на инъекцию
JP5580210B2 (ja) 手術前治療
JP7421558B2 (ja) 組織修復に適用されるピルフェニドンを含有する半固体油性医薬組成物
CA2775317C (en) Topical formulation for diabetic foot ulcers
EP2994120B1 (en) Alpha adrenergic agonists for the treatment of tissue trauma
KR102221499B1 (ko) 위축성 피부 흉터를 치료하기 위한 프로스타글라딘 F2α 및 그 유사체
US20190000936A1 (en) Prophylactic normalization of cutaneous wound repair
US20240100085A1 (en) Methods and compositions for therapeutic skin treatments in dermatological procedures affecting skin's barrier
WO2015181746A1 (en) Gel form of a heparin sodium salt for dermal administration, and a method for its preparation.
CA3216907A1 (en) Methods of using a smalll molecule chemical compound to reduce the appearance of post-acne atrophic scarring
US20240148842A1 (en) Proteolytic enzyme mixture for treating psoriasis
US20210177740A1 (en) Transpore delivery of cannabinoid and uses thereof
US20190021995A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses
KR20200062071A (ko) 지방 생성을 자극하는 펩타이드, 조성 및 방법
KR20140096172A (ko) 주입으로 인한 피부 반응 감소를 위한 필러와 아드레날린 수용체 작용제의 주사가능한 조합
HK1222558B (en) Alpha adrenergic agonists for the treatment of tissue trauma

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240224

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240224